MiMedx Group (MDXG +5.96%), announced Monday that results from a randomized controlled trial for its EpiFix wound-care allograft have been published in the International Wound Journal.
The clinical trial included patients with diabetic foot ulcers of at least four weeks' duration without infection, having adequate blood supply. Patients were broken into two groups, one receiving standard care alone, the other standard care plus EpiFix. After four and six weeks of treatment, the overall healing rate of patients treated with EpiFix was 77% and 92%, respectively, whereas standard care healed 0% and 8% of the wounds, respectively. The rate of healing with EpiFix exceeded that of standard treatment as well.
According to the World Health Organization, diabetes will affect 366 million people worldwide -- up from 171 million in 2000. Approximately 25% of diabetics will develop a chronic non-healing ulcer over their lifetime. Diabetic foot ulcers occur in 15% of all patients with diabetes and precede 84% of all lower leg amputations.
EpiFix makes use of dehydrated human amniotic membrane to heal these ulcers. At room temperature, EpiFix can have a shelf life of five years and retains the properties of the natural membrane. Although there are similar, competing products on the market, the superior performance of EpiFix compared with rival products (not yet proven by published studies) could help to make the company a market leader in the treatment of diabetic foot ulcers.
MiMedx Diabetes Product Produces Positive Test Results
By Rich Smith – Jun 10, 2013 at 6:24PM
NASDAQ: MDXG
MiMedx Group
Market Cap
$1.0B
Today's Change
(5.96%) $0.41
Current Price
$7.29
Price as of October 29, 2025 at 3:20 PM ET
EpiFix repairs diabetes-inflicted ulcers at startlingly high rates.
About the Author
Rich Smith is a contributing Motley Fool defense and stock market analyst covering publicly traded and emerging companies in defense, space, aerospace, and other sectors. Prior to The Motley Fool, Rich practiced international corporate law for Clifford Chance in Russia, and for the Russian-Ukrainian Legal Group in Moscow, Kyiv, and Washington, D.C. He holds a bachelor’s degree in international relations from the College of William & Mary, a law degree from the University of Baltimore, and a language certification from the International Institute of Russian Language & Culture in Tver, Russian Federation. The Globe and Mail once featured him as “one of the best stock pickers since 2009.”